Pulsar Capital-owned TruDoc buys Mumbai's Wellthy Therapeutics
TruDoc Healthcare, the GCC's telehealth and virtual care provider, has acquired Mumbai-based chronic disease management platform Wellthy Therapeutics, according to a company statement.
Wellthy Therapeutics, a digital therapeutics (DTx) company, develops and deploys digital therapeutic candidates for commercialisation in indications across cardiology, nephrology and diabetes.
It helps medication and health brands achieve their commercial goals by building and launching customised digital health solutions, powered by its disease-agnostic, modular, software-as-a-medical-device (SaMD) platform, according to the company website.
Wellthy Therapeutics is backed by investors Ranjan Pai, GrowX and BeeNext.
Pulsar Capital is a private equity fund focused on alternative investments across diversified sectors in India, South Asia, Middle East and Africa. Pulsar Capital, a growth stage investment fund floated by former TPG managing director Vish Narain, acquired TruDoc last September.
With TruDoc's leadership in the GCC and Wellthy’s proven track record in Asia, this alliance is poised to reinforce TruDoc’s leading position in the region as a tech-enabled primary care provider, stated the press release.
«This partnership accelerates our progress towards our impact goal, broadening our reach while enhancing patient outcomes,» said Abhishek Shah, founder of Wellthy Therapeutics. The combined capabilities are uniquely positioned to significantly lower healthcare expenses, contribute to savings, and reduce unnecessary hospital
